Two Sigma Advisers
OKUR

Two Sigma Advisers’s OnKure Therapeutics OKUR Stock Holding History

Two Sigma Advisers’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,608
Closed -$77.2K – 2273
2025
Q4 		$77.2K Hold
26,608
– – ﹤0.01% 2254
2025
Q3 		$73.2K Sell
26,608
-220
-0.8% -$545 ﹤0.01% 2250
2025
Q2 		$64.1K Sell
26,828
-800
-3% -$2.1K ﹤0.01% 2241
2025
Q1 		$119K Buy
27,628
+13,400
+94% +$75.4K ﹤0.01% 2221
2024
Q4 		$122K Sell
14,228
-8,402
-37% -$127K ﹤0.01% 2195
2024
Q3 		$385K Buy
22,630
+15,140
+202% +$224K ﹤0.01% 1817
2024
Q2 		$113K Buy
7,490
+5,870
+362% +$99.5K ﹤0.01% 2308
2024
Q1 		$26.9K Buy
+1,620
New +$26.7K ﹤0.01% 2387

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Advisers's OKUR Position: Q1 2026 in Review

Two Sigma Advisers sold out of OnKure Therapeutics (OKUR) in Q1 2026, closing a stake of 26,608 shares — an estimated $77.2K sold.

Two Sigma Advisers first reported a position in OKUR in Q1 2024 and held it in 8 quarters. The position peaked at $385K in Q3 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Two Sigma Advisers reported no remaining OnKure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 26,608 OnKure Therapeutics shares in Q1 2026, an estimated $77.2K.
  • Two Sigma Advisers first reported a position in OnKure Therapeutics in Q1 2024 and held it in 8 quarters.
  • Two Sigma Advisers's OnKure Therapeutics position peaked at $385K in Q3 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.